This glaucoma treatments developer is expected to post quarterly loss of $0.51 per share in its upcoming report, which represents a year-over-year change of +7.3%. Revenues are expected to be $88.41 million, up 10% from the year-ago quarter. Glaukos is a member of the Zacks Medical - Instruments industry. One other stock in the same industry, Teleflex (TFX) , finished the last trading session 0.7% higher at $200.03. TFX has returned -2.9% over the past month. Glaukos (GKOS) shares rallied 3.7% in the last t ...

Glaukos (GKOS) witnessed strong momentum in the year-to-date period. Shares of the company rallied 40.4% compared with 5.2% growth of the industry. The S&P 500 Composite has risen 11% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Headquartered in San Clemente, CA, Glaukos is an ophthalmic medical technology and pharmaceutical company. It is focused on the developme ...

Shares of Glaukos Corporation (GKOS) scaled a new 52-week high of $111.47 on May 13, before closing the session slightly lower at $108.36. Over the past year, this Zacks Rank #3 (Hold) stock has surged 80.9% compared with the 5.8% rise of the industry and the S&P 500's 26.5% growth. The company's expected growth rate of 0.4% for 2024 compares with the industry's growth projection of 14.1%. Glaukos is witnessing an upward trend in its stock price, prompted by its strength in its flagship iStent. The optimism ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission file number: 001-37463 GLAUKOS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

Glaukos Corporation (GKOS) reported first-quarter 2024 adjusted loss of 70 cents per share, which is 20.7% wider than the Zacks Consensus Estimate of a loss of 58 cents. The figure was also wider than the year-ago quarter’s adjusted loss of 59 cents per share.The GAAP loss per share was 82 cents compared with the prior-year quarter’s reported loss of 72 cents.Revenue DetailsGlaukos registered revenues of $85.6 million in the first quarter, up 16% year over year on a reported and constant currency (cc) basis ...

Glaukos (GKOS) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20.69%. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.56 per share when it actually produced a loss of $0.63, delivering a surprise of -12.50%.Over the last four quarters, the comp ...

Exhibit 99.2 MAY 1, 2024 GLAUKOS CORPORATION (NYSE: GKOS) FIRST QUARTER 2024 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation's recent financial and operational performance and general business outlook. | Date: | May 1, 2024 | | --- | --- | | Time: | 4:30 p.m. ET / 1:30 p.m. PT | | Dial-in numbers: | 1-888-210-2212 (U.S.), 1-646-960-0390 (International) | ...

Shares of Glaukos Corporation (GKOS) scaled a new 52-week high of $97.77 on Apr 5, before closing the session slightly lower at $96.77.Over the past year, this Zacks Rank #3 (Hold) stock has surged 98.8% compared with the 8.6% rise of the industry and the S&P 500’s 27.1% growth.The company’s expected growth rate of 3.9% for 2024 compares with the industry’s growth projection of 13.5%. Glaukos’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average ...

Glaukos Corporation (GKOS) recently announced that its prostaglandin analog iDose TR (travoprost intracameral implant) 75 mcg was assigned permanent Healthcare Common Procedure Coding System J-code by the U.S. Centers for Medicare and Medicaid Services (CMS). This prostaglandin analog is indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.The new J-code for iDose TR, J7355, is likely to become effective starting Jul 1, 2024. It is expected to ...

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this currently Zacks Rank #3 (Hold) company have risen 15.3% in the past six months compared with the industry’s 13.6% growth. The S&P 500 Index has also increased 12.7% in the same time frame.Glaukos, with a market capitalization of $4.3 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects ...